Background: The role of tumor markers in the diagnosis and prognosis of lung cancer is under investigation. Objectives: The aim of this study was to investigate the diagnostic and prognostic significance of pre-therapeutic levels of various serum tumor markers, CYFRA 21-1, neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), CA 125 and squamous cell carcinoma antigen (SCCAg), in patients with lung cancer. Methods: We studied 102 consecutive patients (mean age 65.2 ± 11 years) with newly diagnosed lung cancer (96 males, 94%, with a mean age of 66.3 ± 10.5 years). All patients had a 5-year follow-up. Measurements of the serum tumor markers were performed on initial diagnosis. Results: Eighty-four patients (82%) had non-small-cell lung cancer (NSCLC) and 18 (18%) small-cell lung cancer (SCLC). From the 84 patients with NSCLC, 34 patients (33%) had squamous-cell lung cancer, 23 (22%) adenocarcinoma and 23 (22%) large-cell carcinomas. The overall median survival was 8.5 months. All SCLC patients had extensive disease with a median survival of 10.1 months and NSCLC patients of 8.4 months. Significant differences in the mean values of NSE and CYFRA 21-1 were observed between SCLC and NSCLC. In NSCLC, CYFRA 21-1, TPA, CA 125 and SCCAg serum levels were related to the stage of the disease at diagnosis, and CYFRA 21-1, NSE, TPA and CA-125 were related to a poor outcome. None of the above tumor markers was related to survival in the SCLC group. Conclusion: CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. Also, CYFRA 21-1 with TPA and CA 125 may provide useful information regarding the staging of the disease at diagnosis and the prognosis of patients with NSCLC.

1.
Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 1994;44:7–26.
2.
Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710–1717.
3.
Albain KS, Crowley JJ, Livingston RB: Long term survival and toxicity in small cell lung cancer: Expanded Southwest Oncology Group experience. Chest 1991;99:1425–1432.
4.
Rawson NSB, Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597–604.
5.
Albain K, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991;9:1618–1626.
6.
Ferrigno D, Buccheri G, Biggi A: Serum tumour markers in lung cancer: History, biology and clinical applications. Eur Respir J 1994;7:186–197.
7.
Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E: Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163–169.
8.
Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmitw R: Serum neuron-specific enolase is a useful tumour marker for small cell lung cancer. Cancer 1990;65:1386–1390.
9.
Watine J, Charet JC: Primary small-cell bronchial cancer: Value of serum tumor markers in the prognostic evaluation. Presse Méd 1999;28:1541–1546.
10.
Brechot JM, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J, Chastang C: Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients. Eur J Cancer 1997;33:385–391.
11.
Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, Bisetti A, Ameglio F: Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA 21-1. Eur Respir J 1995;8:1136–1140.
12.
Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61–66.
13.
Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldera S, Bombardieri E: Tumour markers CEA, NSE, SCC, TPA and CYFRA 21-1 in resectable non-small cell lung cancer. Anticancer Res 1999;19:3613–3618.
14.
Niklinski J, Furman M, Burzykowski T, Chyczewski L, Laudanski J, Chyczewska E, Rapellino M: Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 1996;74:956–960.
15.
Giovanella L, Piantanida R, Ceriani L, Bandera M, Novario R, Bianchi L, Roncari G: Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.2) as tumor markers in small cell lung cancer: Clinical evaluation and biological hypothesis. Int J Biol Markers 1997;12:22–26.
16.
Jorgensen LGM, Osterlind K, Hansen HH, Cooper EH: The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 1988;58:805–807.
17.
Diez M, Torres A, Ortega L, Maestro M, Hernando F, Gomez A, Picardo A, Granell J, Balibrea JL: Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology 1993;50:127–131.
18.
Vinolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, Grau JJ, Balesta AM, Estape J: Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report. Anticancer Res 1998;18:631–634.
19.
Margolese RG, Kreisman H, Wolkove N, Cohen C, Frank H: Recent advances in management of lung cancer. Adv Surg 1981;15:189–224.
20.
Buccheri G, Ferrigno D, Vola F: Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993;10:21–33.
21.
Diez M, Cerdan FJ, Ortega D, Torres A, Gomez A, Picardo A, Balibrea JL: Evaluation of serum CA125 as a tumor marker in non-small-cell lung cancer. Cancer 1991;67:150–154.
22.
Diez M, Torres A, Pollan M, Gomez A, Ortega D, Maestro ML, Granell J, Balibrea JL: Prognostic significance of serum CA125 antigen assay in patients with non-small cell lung cancer. Cancer 1994;73:1368–1376.
23.
Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A: Serum CA125 level is a good prognostic indicator in lung cancer. J Cancer 1990;62:676–678.
24.
Cheah PL, Liam CK, Yap SF, Looi LM: Squamous cell carcinoma antigen as an adjunct tumour marker in primary carcinoma of the lung. J Clin Pathol 1994;47:535–537.
25.
Sanchez De Cos J, Masa F, de la Cruz JL, Disdier C, Vergara C: Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest 1994;105:773–776.
26.
Zochbauer-Muller S, Minna JD: The biology of lung cancer including potential clinical applications. Chest Surg Clin N Am 2000;10:691–708.
27.
Wright GS, Gruidl ME: Early detection and prevention of lung cancer. Curr Opin Oncol 2000;12:143–148.
28.
Froudarakis ME, Sourvinos G, Fournel P, Bouros D, Vergnon JM, Spandidos DA, Siafakas NM: Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small-cell lung cancer. Chest 1998;113:1091–1094.
29.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392:300–303.
30.
Gruidl ME, Shaw Wright GL: Potential biomarkers for the early detection of lung cancer. J Thorac Imaging 2000;15:13–20.
31.
Pina TC, Zapata IT, Lopez JB, Perez JL, Paricio PP, Hernandez PM: Tumor markers in lung cancer: Does the method of obtaining the cut-off point and reference population influence diagnostic yield? Clin Biochem 1999;32:467–472.
32.
Watine J: Laboratory variables as additional staging parameters in patients with small-cell lung carcinoma. A systematic review. Clin Chem Lab Med 1999;37:931–938.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.